Targeted cancer drugs finally living up to the hype

Targeted cancer drugs finally living up to the hype
Big pharmaceutical companies are backing so-called antibody-drug conjugates. (Image: Bloomberg)
Bloomberg
By Lisa JarvisCancer drugs that work like heat-seeking missiles to deliver chemicals directly to tumours are having a bit of a moment. Pharmaceutical companies, in need of assets to counter flagging sales, are making these so-called antibody-drug conjugates the technology of choice in oncology dealmaking, as illustrated by the recent US$10.1 billion (NZ$16.5b) acquisition of ImmunoGen by AbbVie.If that trend sounds vaguely familiar, you have probably been following the pharma industry for too long. The field has gone through waves of hype and i...

More Bloomberg

Apple updates Pro products with M5 chip
Technology

Apple updates Pro products with M5 chip

The devices don’t offer major exterior design changes.

Bloomberg 18 Oct 2025
A chart climate denialists can’t ignore
Climate change Opinion

A chart climate denialists can’t ignore

Hausfather’s chart shows that about 3% of the 1930s temperature records still stand.

Bloomberg 11 Oct 2025
Altman’s AI power grab is tone deaf and infeasible
Technology Opinion

Altman’s AI power grab is tone deaf and infeasible

A bit more nuance and creativity, plus a dash of realism, is in order.

Bloomberg 04 Oct 2025
Will AI make lawyers richer or put them out of work?
Technology Opinion

Will AI make lawyers richer or put them out of work?

Lawyers could be with us for a while; it's just not clear how they'll get paid.

Bloomberg 07 Sep 2025